Jasper Therapeutics Inc (JSPR)

NASDAQ
Currency in USD
6.885
+0.045(+0.66%)
Real-time Data
JSPR Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Fair Value
Day's Range
6.8366.885
52 wk Range
5.25031.010
Key Statistics
Edit
Prev. Close
6.84
Open
6.86
Day's Range
6.836-6.885
52 wk Range
5.25-31.01
Volume
12.24K
Average Volume (3m)
481.16K
1-Year Change
-53.88%
Book Value / Share
5.54
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
JSPR Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
61.444
Upside
+792.44%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash
Show more

Jasper Therapeutics Inc Company Profile

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company’s lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and conditioning regimens for stem cell transplantation. In addition, it is also developing stem cell transplants for rare diseases such as sickle cell disease, fanconi anemia, chronic granulomatous diseases, and GATA2 MDS, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.

Jasper Therapeutics Inc SWOT Analysis


Briquilimab's Promise
Explore Jasper Therapeutics' lead product, briquilimab, and its potential to revolutionize treatment for chronic urticaria, with projected peak sales of $500-550 million.
Clinical Milestones
Delve into Jasper's ongoing trials, including the BEACON and SPOTLIGHT studies, with key data readouts expected to significantly impact the company's valuation.
Market Positioning
Learn how Jasper aims to differentiate briquilimab from competitors like Celldex's barzolvolimab, potentially offering improved safety and dosing convenience.
Analyst Outlook
Discover why analysts set price targets ranging from $63 to $86, reflecting optimism about Jasper's potential in the mast cell-mediated disease market.
Read full SWOT analysis

Compare JSPR to Peers and Sector

Metrics to compare
JSPR
Peers
Sector
Relationship
P/E Ratio
−1.6x−1.3x−0.6x
PEG Ratio
−0.05−0.010.00
Price/Book
1.2x0.9x2.6x
Price / LTM Sales
-12.1x3.1x
Upside (Analyst Target)
-418.1%51.7%
Fair Value Upside
Unlock18.1%7.5%Unlock

Analyst Ratings

11 Buy
0 Hold
0 Sell
Ratings:
11 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 61.444
(+792.44% Upside)

Earnings

Latest Release
May 10, 2024
EPS / Forecast
-- / -1.45
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

People Also Watch

1.94
NMRA
+1.57%
8.03
CADL
+2.82%
16.5500
GRRR
+5.62%
2.0000
MYSZ
-2.44%

FAQ

What Is the Jasper Therapeutics (JSPR) Stock Price Today?

The Jasper Therapeutics stock price today is 6.885

What Stock Exchange Does Jasper Therapeutics Trade On?

Jasper Therapeutics is listed and trades on the NASDAQ stock exchange.

What Is the Stock Symbol for Jasper Therapeutics?

The stock symbol for Jasper Therapeutics is "JSPR."

What Is the Jasper Therapeutics Market Cap?

As of today, Jasper Therapeutics market cap is 102.61M.

What is Jasper Therapeutics Earnings Per Share?

The Jasper Therapeutics EPS is -4.67.

From a Technical Analysis Perspective, Is JSPR a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.